AR and non-Hodgkin lymphoma: Patients with EBER+ AR‐NHL, compared to patients with EBER− AR‐NHL, exhibited higher frequencies of bulky tumors (78.9% vs. 21.1%, p = 0.024) and a greater Ki‐67 proliferation index (66.7% vs. 33.3%, p = 0.020), in accordance with previous research.5